Marksans Pharma Limited has informed the Exchange regarding a press release dated Jun 19, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in the UK, Relonchem Limited receives Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution.".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly-owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution. Oxybutynin is used to treat overactive bladder and related urinary conditions. The approval allows Relonchem to market this product in the UK market. The company already has manufacturing facilities approved by USFDA, UKMHRA, and Australian TGA, and markets generic formulations globally across therapeutic segments including CVS, CNS, anti-diabetic, pain management, gastro, and anti-allergies. No revenue impact or order size was disclosed in this announcement.
This is a routine regulatory approval that adds another product to the company's UK portfolio through its subsidiary, but the announcement does not indicate any material financial impact. Likely a neutral-to-slightly-positive signal for the stock as it strengthens the UK subsidiary's product basket.